ID   AF9_HUMAN               Reviewed;         568 AA.
AC   P42568; B1AMQ2; B2R7B3; B7Z755; D3DRJ8; Q8IVB0;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   28-JUN-2023, entry version 189.
DE   RecName: Full=Protein AF-9 {ECO:0000305};
DE   AltName: Full=ALL1-fused gene from chromosome 9 protein {ECO:0000303|PubMed:10861294};
DE   AltName: Full=Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein {ECO:0000303|PubMed:16001262};
DE   AltName: Full=YEATS domain-containing protein 3;
GN   Name=MLLT3 {ECO:0000303|PubMed:16001262, ECO:0000312|HGNC:HGNC:7136};
GN   Synonyms=AF9 {ECO:0000303|PubMed:10861294}, YEATS3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL TRANSLOCATION WITH
RP   KMT2A.
RX   PubMed=8506309; DOI=10.1073/pnas.90.10.4631;
RA   Nakamura T., Alder H., Gu Y., Prasad R., Canaani O., Kamada N., Gale R.P.,
RA   Lange B., Crist W.M., Nowell P.C., Croce C.M., Canaani E.;
RT   "Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute
RT   leukemia share sequence homology and/or common motifs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:4631-4635(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH BCOR.
RX   PubMed=10898795;
RA   Huynh K.D., Fischle W., Verdin E., Bardwell V.J.;
RT   "BCoR, a novel corepressor involved in BCL-6 repression.";
RL   Genes Dev. 14:1810-1823(2000).
RN   [7]
RP   CHROMOSOMAL TRANSLOCATION.
RX   PubMed=10861294; DOI=10.1093/hmg/9.11.1671;
RA   Strissel P.L., Strick R., Tomek R.J., Roe B.A., Rowley J.D.,
RA   Zeleznik-Le N.J.;
RT   "DNA structural properties of AF9 are similar to MLL and could act as
RT   recombination hot spots resulting in MLL/AF9 translocations and
RT   leukemogenesis.";
RL   Hum. Mol. Genet. 9:1671-1679(2000).
RN   [8]
RP   INTERACTION WITH CBX8.
RX   PubMed=11313972; DOI=10.1038/sj.onc.1204108;
RA   Garcia-Cuellar M.P., Zilles O., Schreiner S.A., Birke M., Winkler T.H.,
RA   Slany R.K.;
RT   "The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein
RT   recruits human Polycomb 3.";
RL   Oncogene 20:411-419(2001).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION.
RX   PubMed=16001262; DOI=10.1007/s00439-005-0004-1;
RA   Pramparo T., Grosso S., Messa J., Zatterale A., Bonaglia M.C., Chessa L.,
RA   Balestri P., Rocchi M., Zuffardi O., Giorda R.;
RT   "Loss-of-function mutation of the AF9/MLLT3 gene in a girl with neuromotor
RT   development delay, cerebellar ataxia, and epilepsy.";
RL   Hum. Genet. 118:76-81(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 AND SER-483, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-288; SER-294 AND SER-483, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-412 AND SER-419, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   FUNCTION, AND IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=20471948; DOI=10.1016/j.molcel.2010.04.013;
RA   He N., Liu M., Hsu J., Xue Y., Chou S., Burlingame A., Krogan N.J.,
RA   Alber T., Zhou Q.;
RT   "HIV-1 Tat and host AFF4 recruit two transcription elongation factors into
RT   a bifunctional complex for coordinated activation of HIV-1 transcription.";
RL   Mol. Cell 38:428-438(2010).
RN   [15]
RP   FUNCTION, AND IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=20159561; DOI=10.1016/j.molcel.2010.01.026;
RA   Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L.,
RA   Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A.;
RT   "AFF4, a component of the ELL/P-TEFb elongation complex and a shared
RT   subunit of MLL chimeras, can link transcription elongation to leukemia.";
RL   Mol. Cell 37:429-437(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-483, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=22195968; DOI=10.1016/j.molcel.2011.12.008;
RA   Smith E.R., Lin C., Garrett A.S., Thornton J., Mohaghegh N., Hu D.,
RA   Jackson J., Saraf A., Swanson S.K., Seidel C., Florens L., Washburn M.P.,
RA   Eissenberg J.C., Shilatifard A.;
RT   "The little elongation complex regulates small nuclear RNA transcription.";
RL   Mol. Cell 44:954-965(2011).
RN   [18]
RP   INTERACTION OF FUSION PROTEIN KMT2A-MLLT3 WITH MEN1.
RX   PubMed=22936661; DOI=10.1182/blood-2012-05-429274;
RA   Shi A., Murai M.J., He S., Lund G., Hartley T., Purohit T., Reddy G.,
RA   Chruszcz M., Grembecka J., Cierpicki T.;
RT   "Structural insights into inhibition of the bivalent menin-MLL interaction
RT   by small molecules in leukemia.";
RL   Blood 120:4461-4469(2012).
RN   [19]
RP   REVIEW ON THE SUPER ELONGATION COMPLEX.
RX   PubMed=22895430; DOI=10.1038/nrm3417;
RA   Luo Z., Lin C., Shilatifard A.;
RT   "The super elongation complex (SEC) family in transcriptional control.";
RL   Nat. Rev. Mol. Cell Biol. 13:543-547(2012).
RN   [20]
RP   INTERACTION WITH ALKBH4.
RX   PubMed=23145062; DOI=10.1371/journal.pone.0049045;
RA   Bjornstad L.G., Meza T.J., Otterlei M., Olafsrud S.M., Meza-Zepeda L.A.,
RA   Falnes P.O.;
RT   "Human ALKBH4 interacts with proteins associated with transcription.";
RL   PLoS ONE 7:E49045-E49045(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 AND SER-483, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INTERACTION OF FUSION PROTEIN KMT2A-MLLT3 WITH PSIP1 AND MEN1.
RX   PubMed=25305204; DOI=10.1182/blood-2014-01-550079;
RA   Murai M.J., Pollock J., He S., Miao H., Purohit T., Yokom A., Hess J.L.,
RA   Muntean A.G., Grembecka J., Cierpicki T.;
RT   "The same site on the integrase-binding domain of lens epithelium-derived
RT   growth factor is a therapeutic target for MLL leukemia and HIV.";
RL   Blood 124:3730-3737(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-339, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-339, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=31776511; DOI=10.1038/s41586-019-1790-2;
RA   Calvanese V., Nguyen A.T., Bolan T.J., Vavilina A., Su T., Lee L.K.,
RA   Wang Y., Lay F.D., Magnusson M., Crooks G.M., Kurdistani S.K.,
RA   Mikkola H.K.A.;
RT   "MLLT3 governs human haematopoietic stem-cell self-renewal and
RT   engraftment.";
RL   Nature 576:281-286(2019).
RN   [26]
RP   INTERACTION WITH CDK9, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=30134174; DOI=10.1016/j.celrep.2018.07.064;
RA   Ghosh K., Tang M., Kumari N., Nandy A., Basu S., Mall D.P., Rai K.,
RA   Biswas D.;
RT   "Positive Regulation of Transcription by Human ZMYND8 through Its
RT   Association with P-TEFb Complex.";
RL   Cell Rep. 24:2141-2154(2018).
RN   [27] {ECO:0007744|PDB:2LM0}
RP   STRUCTURE BY NMR OF 490-568 IN COMPLEX WITH AFF1.
RX   PubMed=23260655; DOI=10.1016/j.str.2012.11.011;
RA   Leach B.I., Kuntimaddi A., Schmidt C.R., Cierpicki T., Johnson S.A.,
RA   Bushweller J.H.;
RT   "Leukemia fusion target AF9 is an intrinsically disordered transcriptional
RT   regulator that recruits multiple partners via coupled folding and
RT   binding.";
RL   Structure 21:176-183(2013).
RN   [28] {ECO:0007744|PDB:4TMP}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1-138 IN COMPLEX WITH H3K9AC
RP   PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-28;
RP   HIS-56; SER-58; PHE-59; GLY-77; TYR-78; PHE-81 AND ASP-103.
RX   PubMed=25417107; DOI=10.1016/j.cell.2014.09.049;
RA   Li Y., Wen H., Xi Y., Tanaka K., Wang H., Peng D., Ren Y., Jin Q.,
RA   Dent S.Y., Li W., Li H., Shi X.;
RT   "AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79
RT   methylation.";
RL   Cell 159:558-571(2014).
RN   [29] {ECO:0007744|PDB:5HJB, ECO:0007744|PDB:5HJD}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 1-138 IN COMPLEX WITH H3K9CR
RP   PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-28;
RP   HIS-56; SER-58; PHE-59; GLY-77 AND TYR-78.
RX   PubMed=27105114; DOI=10.1016/j.molcel.2016.03.028;
RA   Li Y., Sabari B.R., Panchenko T., Wen H., Zhao D., Guan H., Wan L.,
RA   Huang H., Tang Z., Zhao Y., Roeder R.G., Shi X., Allis C.D., Li H.;
RT   "Molecular coupling of histone crotonylation and active transcription by
RT   AF9 YEATS domain.";
RL   Mol. Cell 62:181-193(2016).
RN   [30] {ECO:0007744|PDB:2NDF, ECO:0007744|PDB:2NDG}
RP   STRUCTURE BY NMR OF 1-138, FUNCTION, DOMAIN, AND MUTAGENESIS OF PHE-59 AND
RP   TYR-78.
RX   PubMed=27545619; DOI=10.1016/j.str.2016.05.023;
RA   Zhang Q., Zeng L., Zhao C., Ju Y., Konuma T., Zhou M.M.;
RT   "Structural insights into histone crotonyl-lysine recognition by the AF9
RT   YEATS domain.";
RL   Structure 24:1606-1612(2016).
RN   [31] {ECO:0007744|PDB:5YYF}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1-138 IN COMPLEX WITH INHIBITOR,
RP   FUNCTION, DOMAIN, AND ACTIVITY REGULATION.
RX   PubMed=30374167; DOI=10.1038/s41589-018-0144-y;
RA   Li X., Li X.M., Jiang Y., Liu Z., Cui Y., Fung K.Y., van der Beelen S.H.E.,
RA   Tian G., Wan L., Shi X., Allis C.D., Li H., Li Y., Li X.D.;
RT   "Structure-guided development of YEATS domain inhibitors by targeting pi-
RT   pi-pi stacking.";
RL   Nat. Chem. Biol. 14:1140-1149(2018).
RN   [32] {ECO:0007744|PDB:6MIL, ECO:0007744|PDB:6MIM}
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-138 IN COMPLEX WITH H3K9CR
RP   PEPTIDE, FUNCTION, DOMAIN, AND MUTAGENESIS OF 61-ARG--LYS-67; 78-TYR-ALA-79
RP   AND TYR-78.
RX   PubMed=30385749; DOI=10.1038/s41467-018-07072-6;
RA   Klein B.J., Vann K.R., Andrews F.H., Wang W.W., Zhang J., Zhang Y.,
RA   Beloglazkina A.A., Mi W., Li Y., Li H., Shi X., Kutateladze A.G.,
RA   Strahl B.D., Liu W.R., Kutateladze T.G.;
RT   "Structural insights into the pi-pi-pi stacking mechanism and DNA-binding
RT   activity of the YEATS domain.";
RL   Nat. Commun. 9:4574-4574(2018).
CC   -!- FUNCTION: Chromatin reader component of the super elongation complex
CC       (SEC), a complex required to increase the catalytic rate of RNA
CC       polymerase II transcription by suppressing transient pausing by the
CC       polymerase at multiple sites along the DNA (PubMed:20159561,
CC       PubMed:20471948, PubMed:25417107, PubMed:27105114, PubMed:27545619).
CC       Specifically recognizes and binds acylated histone H3, with a
CC       preference for histone H3 that is crotonylated (PubMed:25417107,
CC       PubMed:27105114, PubMed:27545619, PubMed:30374167, PubMed:30385749).
CC       Crotonylation marks active promoters and enhancers and confers
CC       resistance to transcriptional repressors (PubMed:25417107,
CC       PubMed:27105114, PubMed:27545619). Recognizes and binds histone H3
CC       crotonylated at 'Lys-9' (H3K9cr), and with slightly lower affinity
CC       histone H3 crotonylated at 'Lys-18' (H3K18cr) (PubMed:27105114). Also
CC       recognizes and binds histone H3 acetylated and butyrylated at 'Lys-9'
CC       (H3K9ac and H3K9bu, respectively), but with lower affinity than
CC       crotonylated histone H3 (PubMed:25417107, PubMed:27105114,
CC       PubMed:30385749). In the SEC complex, MLLT3 is required to recruit the
CC       complex to crotonylated histones (PubMed:27105114, PubMed:27545619).
CC       Recruitment of the SEC complex to crotonylated histones promotes
CC       recruitment of DOT1L on active chromatin to deposit histone H3 'Lys-79'
CC       methylation (H3K79me) (PubMed:25417107). Plays a key role in
CC       hematopoietic stem cell (HSC) maintenance by preserving, rather than
CC       confering, HSC stemness (PubMed:31776511). Acts by binding to the
CC       transcription start site of active genes in HSCs and sustaining level
CC       of H3K79me2, probably by recruiting DOT1L (PubMed:31776511).
CC       {ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948,
CC       ECO:0000269|PubMed:25417107, ECO:0000269|PubMed:27105114,
CC       ECO:0000269|PubMed:27545619, ECO:0000269|PubMed:30374167,
CC       ECO:0000269|PubMed:30385749, ECO:0000269|PubMed:31776511}.
CC   -!- ACTIVITY REGULATION: Crotonylated lysine binding is strongly inhibited
CC       by the peptide XL-07i, carrying a 2-furancarbonyl side chain and capped
CC       with a hydrophobic carboxybenzyl group (PubMed:30374167). XL-07i
CC       targets the unique pi-pi-pi stacking interaction at the crotonylation
CC       recognition site (PubMed:30374167). {ECO:0000269|PubMed:30374167}.
CC   -!- SUBUNIT: Component of the super elongation complex (SEC), at least
CC       composed of EAF1, EAF2, CDK9, MLLT3/AF9, AFF (AFF1 or AFF4), the P-TEFb
CC       complex and ELL (ELL, ELL2 or ELL3) (PubMed:20159561, PubMed:20471948,
CC       PubMed:22195968, PubMed:23260655, PubMed:25417107, PubMed:30134174).
CC       Interacts with BCOR (PubMed:10898795). Interacts with CBX8
CC       (PubMed:11313972). Interacts with ALKBH4 (PubMed:23145062).
CC       {ECO:0000269|PubMed:10898795, ECO:0000269|PubMed:11313972,
CC       ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948,
CC       ECO:0000269|PubMed:22195968, ECO:0000269|PubMed:23145062,
CC       ECO:0000269|PubMed:23260655, ECO:0000269|PubMed:25417107,
CC       ECO:0000269|PubMed:30134174}.
CC   -!- INTERACTION:
CC       P42568; P51825: AFF1; NbExp=7; IntAct=EBI-716132, EBI-2610180;
CC       P42568; Q9UHB7: AFF4; NbExp=4; IntAct=EBI-716132, EBI-395282;
CC       P42568; Q9NXW9: ALKBH4; NbExp=5; IntAct=EBI-716132, EBI-8637516;
CC       P42568; Q92624: APPBP2; NbExp=4; IntAct=EBI-716132, EBI-743771;
CC       P42568; Q6W2J9-1: BCOR; NbExp=2; IntAct=EBI-716132, EBI-16028932;
CC       P42568; Q9HC52: CBX8; NbExp=2; IntAct=EBI-716132, EBI-712912;
CC       P42568; Q8TEK3: DOT1L; NbExp=6; IntAct=EBI-716132, EBI-2619253;
CC       P42568; Q8IZU1: FAM9A; NbExp=4; IntAct=EBI-716132, EBI-8468186;
CC       P42568; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-716132, EBI-2801965;
CC       P42568; Q5SQQ9-2: VAX1; NbExp=3; IntAct=EBI-716132, EBI-12227803;
CC       P42568; Q7Z3I7: ZNF572; NbExp=3; IntAct=EBI-716132, EBI-10172590;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00376,
CC       ECO:0000269|PubMed:27105114}. Chromosome {ECO:0000269|PubMed:25417107,
CC       ECO:0000269|PubMed:27105114}. Note=Colocalizes with acylated histone H3
CC       (PubMed:25417107, PubMed:27105114). Colocalizes with histone H3
CC       crotonylated at 'Lys-18' (H3K18cr) (PubMed:27105114).
CC       {ECO:0000269|PubMed:25417107, ECO:0000269|PubMed:27105114}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P42568-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P42568-2; Sequence=VSP_054924;
CC   -!- TISSUE SPECIFICITY: Enriched in undifferentiated hematopoietic stem
CC       cells in fetal liver, cord blood and bone marrow.
CC       {ECO:0000269|PubMed:31776511}.
CC   -!- DOMAIN: The YEATS domain specifically recognizes and binds acylated
CC       histones, with a marked preference for histones that are crotonylated
CC       (PubMed:27105114, PubMed:27545619). Also binds histone H3 acetylated at
CC       'Lys-9' (H3K9ac), but with lower affinity (PubMed:25417107,
CC       PubMed:27105114). Binds crotonylated lysine through a non-canonical pi-
CC       pi-pi stacking mechanism (PubMed:30374167, PubMed:30385749). The YEATS
CC       domain also binds DNA (PubMed:30385749). {ECO:0000269|PubMed:25417107,
CC       ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619,
CC       ECO:0000269|PubMed:30374167, ECO:0000269|PubMed:30385749}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MLLT3 is associated
CC       with acute leukemias. Translocation t(9;11)(p22;q23) with KMT2A/MLL1.
CC       The result is a rogue activator protein. Fusion protein KMT2A-MLLT3
CC       interacts with MEN1 and PSIP1 (PubMed:22936661, PubMed:25305204).
CC       {ECO:0000269|PubMed:10861294, ECO:0000269|PubMed:22936661,
CC       ECO:0000269|PubMed:25305204, ECO:0000269|PubMed:8506309}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MLLT3 was observed in
CC       a patient with neuromotor development delay, cerebellar ataxia and
CC       epilepsy. Translocation t(4;9)(q35;p22). {ECO:0000269|PubMed:16001262}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/5/mllt3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13744; AAA58361.1; -; mRNA.
DR   EMBL; AK301474; BAH13491.1; -; mRNA.
DR   EMBL; AK312914; BAG35760.1; -; mRNA.
DR   EMBL; AL354879; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL512635; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL513498; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL163193; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL627410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58631.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58632.1; -; Genomic_DNA.
DR   EMBL; BC036089; AAH36089.1; -; mRNA.
DR   CCDS; CCDS6494.1; -. [P42568-1]
DR   CCDS; CCDS69579.1; -. [P42568-2]
DR   PIR; I39411; I39411.
DR   RefSeq; NP_001273620.1; NM_001286691.1. [P42568-2]
DR   RefSeq; NP_004520.2; NM_004529.3. [P42568-1]
DR   PDB; 2LM0; NMR; -; A=490-568.
DR   PDB; 2MV7; NMR; -; A=500-568.
DR   PDB; 2N4Q; NMR; -; B=500-568.
DR   PDB; 2NDF; NMR; -; A=1-138.
DR   PDB; 2NDG; NMR; -; A=1-138.
DR   PDB; 4TMP; X-ray; 2.30 A; A/C=1-138.
DR   PDB; 5HJB; X-ray; 2.70 A; A=1-138.
DR   PDB; 5HJD; X-ray; 2.81 A; A/C/E/G/K/N/Q/T=1-138.
DR   PDB; 5YYF; X-ray; 1.90 A; A/C=1-138.
DR   PDB; 6B7G; NMR; -; A=500-568.
DR   PDB; 6L5Z; X-ray; 3.05 A; A=1-138.
DR   PDB; 6LS6; X-ray; 2.20 A; A/B=1-138.
DR   PDB; 6MIL; X-ray; 1.93 A; A/C=1-138.
DR   PDB; 6MIM; X-ray; 2.52 A; A/C=1-138.
DR   PDB; 7EIC; X-ray; 1.95 A; A/B=1-138.
DR   PDB; 7EID; X-ray; 2.00 A; A/B=1-138.
DR   PDB; 7VKG; X-ray; 1.83 A; A=1-138.
DR   PDB; 7VKH; X-ray; 2.25 A; A/B=1-138.
DR   PDBsum; 2LM0; -.
DR   PDBsum; 2MV7; -.
DR   PDBsum; 2N4Q; -.
DR   PDBsum; 2NDF; -.
DR   PDBsum; 2NDG; -.
DR   PDBsum; 4TMP; -.
DR   PDBsum; 5HJB; -.
DR   PDBsum; 5HJD; -.
DR   PDBsum; 5YYF; -.
DR   PDBsum; 6B7G; -.
DR   PDBsum; 6L5Z; -.
DR   PDBsum; 6LS6; -.
DR   PDBsum; 6MIL; -.
DR   PDBsum; 6MIM; -.
DR   PDBsum; 7EIC; -.
DR   PDBsum; 7EID; -.
DR   PDBsum; 7VKG; -.
DR   PDBsum; 7VKH; -.
DR   AlphaFoldDB; P42568; -.
DR   BMRB; P42568; -.
DR   SMR; P42568; -.
DR   BioGRID; 110446; 86.
DR   CORUM; P42568; -.
DR   DIP; DIP-56409N; -.
DR   IntAct; P42568; 52.
DR   MINT; P42568; -.
DR   STRING; 9606.ENSP00000369695; -.
DR   BindingDB; P42568; -.
DR   ChEMBL; CHEMBL4295761; -.
DR   GlyGen; P42568; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P42568; -.
DR   PhosphoSitePlus; P42568; -.
DR   BioMuta; MLLT3; -.
DR   DMDM; 215273971; -.
DR   jPOST; P42568; -.
DR   MassIVE; P42568; -.
DR   MaxQB; P42568; -.
DR   PaxDb; P42568; -.
DR   PeptideAtlas; P42568; -.
DR   ProteomicsDB; 55517; -. [P42568-1]
DR   ProteomicsDB; 6833; -.
DR   Antibodypedia; 1068; 311 antibodies from 29 providers.
DR   DNASU; 4300; -.
DR   Ensembl; ENST00000380338.9; ENSP00000369695.4; ENSG00000171843.17. [P42568-1]
DR   Ensembl; ENST00000630269.2; ENSP00000485996.1; ENSG00000171843.17. [P42568-2]
DR   GeneID; 4300; -.
DR   KEGG; hsa:4300; -.
DR   MANE-Select; ENST00000380338.9; ENSP00000369695.4; NM_004529.4; NP_004520.2.
DR   UCSC; uc003zoe.3; human. [P42568-1]
DR   AGR; HGNC:7136; -.
DR   CTD; 4300; -.
DR   DisGeNET; 4300; -.
DR   GeneCards; MLLT3; -.
DR   HGNC; HGNC:7136; MLLT3.
DR   HPA; ENSG00000171843; Low tissue specificity.
DR   MalaCards; MLLT3; -.
DR   MIM; 159558; gene.
DR   neXtProt; NX_P42568; -.
DR   OpenTargets; ENSG00000171843; -.
DR   Orphanet; 402017; Acute myeloid leukemia with t(9;11)(p22;q23).
DR   PharmGKB; PA30852; -.
DR   VEuPathDB; HostDB:ENSG00000171843; -.
DR   eggNOG; KOG3149; Eukaryota.
DR   GeneTree; ENSGT00940000155903; -.
DR   InParanoid; P42568; -.
DR   OMA; RIMYQYD; -.
DR   OrthoDB; 4267365at2759; -.
DR   PhylomeDB; P42568; -.
DR   TreeFam; TF314586; -.
DR   PathwayCommons; P42568; -.
DR   Reactome; R-HSA-112382; Formation of RNA Pol II elongation complex.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-75955; RNA Polymerase II Transcription Elongation.
DR   SignaLink; P42568; -.
DR   SIGNOR; P42568; -.
DR   BioGRID-ORCS; 4300; 25 hits in 1156 CRISPR screens.
DR   ChiTaRS; MLLT3; human.
DR   GeneWiki; MLLT3; -.
DR   GenomeRNAi; 4300; -.
DR   Pharos; P42568; Tchem.
DR   PRO; PR:P42568; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P42568; protein.
DR   Bgee; ENSG00000171843; Expressed in ganglionic eminence and 165 other tissues.
DR   ExpressionAtlas; P42568; baseline and differential.
DR   Genevisible; P42568; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0008023; C:transcription elongation factor complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0140030; F:modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000096; P:positive regulation of Wnt signaling pathway, planar cell polarity pathway; IGI:MGI.
DR   GO; GO:1902275; P:regulation of chromatin organization; IMP:UniProtKB.
DR   GO; GO:2000035; P:regulation of stem cell division; IDA:UniProtKB.
DR   GO; GO:0007379; P:segment specification; IEA:Ensembl.
DR   CDD; cd16906; YEATS_AF-9_like; 1.
DR   DisProt; DP01070; -.
DR   Gene3D; 1.20.1270.290; -; 1.
DR   Gene3D; 2.60.40.1970; YEATS domain; 1.
DR   IDEAL; IID00552; -.
DR   InterPro; IPR040930; AF-9_AHD.
DR   InterPro; IPR038704; YEAST_sf.
DR   InterPro; IPR005033; YEATS.
DR   PANTHER; PTHR47827; AHD DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR47827:SF5; PROTEIN AF-9; 1.
DR   Pfam; PF17793; AHD; 1.
DR   Pfam; PF03366; YEATS; 1.
DR   PROSITE; PS51037; YEATS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Chromosomal rearrangement;
KW   Chromosome; DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..568
FT                   /note="Protein AF-9"
FT                   /id="PRO_0000215921"
FT   DOMAIN          1..138
FT                   /note="YEATS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00376"
FT   REGION          78..80
FT                   /note="Histone H3K9cr binding"
FT                   /evidence="ECO:0000269|PubMed:27105114,
FT                   ECO:0000269|PubMed:30385749, ECO:0007744|PDB:5HJB,
FT                   ECO:0007744|PDB:5HJD, ECO:0007744|PDB:6MIL,
FT                   ECO:0007744|PDB:6MIM"
FT   REGION          106..108
FT                   /note="Histone H3K9cr binding"
FT                   /evidence="ECO:0000269|PubMed:27105114,
FT                   ECO:0000269|PubMed:30385749, ECO:0007744|PDB:5HJB,
FT                   ECO:0007744|PDB:5HJD, ECO:0007744|PDB:6MIL,
FT                   ECO:0007744|PDB:6MIM"
FT   REGION          137..475
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           295..300
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        143..195
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        196..262
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        282..304
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        323..354
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        373..403
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        414..428
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        441..461
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            58
FT                   /note="Histone H3K9cr binding"
FT                   /evidence="ECO:0000269|PubMed:27105114,
FT                   ECO:0000269|PubMed:30385749, ECO:0007744|PDB:5HJB,
FT                   ECO:0007744|PDB:5HJD, ECO:0007744|PDB:6MIL,
FT                   ECO:0007744|PDB:6MIM"
FT   SITE            103
FT                   /note="Histone H3K9cr binding"
FT                   /evidence="ECO:0000269|PubMed:27105114,
FT                   ECO:0000269|PubMed:30385749, ECO:0007744|PDB:5HJB,
FT                   ECO:0007744|PDB:5HJD, ECO:0007744|PDB:6MIL,
FT                   ECO:0007744|PDB:6MIM"
FT   SITE            375
FT                   /note="KMT2A/MLL1 fusion point (in acute myeloid leukemia
FT                   patient CO)"
FT                   /evidence="ECO:0000269|PubMed:8506309"
FT   SITE            481
FT                   /note="KMT2A/MLL1 fusion point (in acute myeloid leukemia
FT                   patient F1)"
FT                   /evidence="ECO:0000269|PubMed:8506309"
FT   MOD_RES         288
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         412
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        339
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..4
FT                   /note="MASS -> M (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054924"
FT   MUTAGEN         28
FT                   /note="F->A: Decreased binding to crotonylated histone H3.
FT                   Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114"
FT   MUTAGEN         56
FT                   /note="H->A: Decreased binding to crotonylated histone H3.
FT                   Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114"
FT   MUTAGEN         58
FT                   /note="S->A: Decreased binding to crotonylated histone H3.
FT                   Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114"
FT   MUTAGEN         59
FT                   /note="F->A: Strongly decreased binding to crotonylated
FT                   histone H3. Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619"
FT   MUTAGEN         61..67
FT                   /note="RPKRVCK->EPERVCE: Decreased DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:30385749"
FT   MUTAGEN         77
FT                   /note="G->A: Decreased binding to crotonylated histone H3.
FT                   Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114"
FT   MUTAGEN         78..79
FT                   /note="YA->WG: Binds equally well acetylated and
FT                   crotonylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:30385749"
FT   MUTAGEN         78
FT                   /note="Y->A: Strongly decreased binding to crotonylated
FT                   histone H3. Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107,
FT                   ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619"
FT   MUTAGEN         78
FT                   /note="Y->W: Does not affect ability to discriminate
FT                   between acetylated and crotonylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:30385749"
FT   MUTAGEN         81
FT                   /note="F->A: Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107"
FT   MUTAGEN         103
FT                   /note="D->A: Decreased binding to acetylated histone H3."
FT                   /evidence="ECO:0000269|PubMed:25417107"
FT   CONFLICT        6
FT                   /note="A -> S (in Ref. 1; AAA58361 and 2; BAG35760)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        173
FT                   /note="S -> G (in Ref. 5; AAH36089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        419
FT                   /note="S -> P (in Ref. 2; BAG35760)"
FT                   /evidence="ECO:0000305"
FT   STRAND          6..19
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          30..37
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   HELIX           39..41
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   TURN            45..47
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          48..54
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          59..61
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          63..90
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          92..94
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          97..104
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   STRAND          114..126
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   HELIX           129..135
FT                   /evidence="ECO:0007829|PDB:5YYF"
FT   HELIX           504..515
FT                   /evidence="ECO:0007829|PDB:2LM0"
FT   HELIX           523..531
FT                   /evidence="ECO:0007829|PDB:2LM0"
FT   STRAND          536..538
FT                   /evidence="ECO:0007829|PDB:2LM0"
FT   STRAND          543..545
FT                   /evidence="ECO:0007829|PDB:2LM0"
FT   TURN            547..549
FT                   /evidence="ECO:0007829|PDB:2LM0"
FT   HELIX           552..561
FT                   /evidence="ECO:0007829|PDB:2LM0"
SQ   SEQUENCE   568 AA;  63351 MW;  0A020B7FB34132F9 CRC64;
     MASSCAVQVK LELGHRAQVR KKPTVEGFTH DWMVFVRGPE HSNIQHFVEK VVFHLHESFP
     RPKRVCKDPP YKVEESGYAG FILPIEVYFK NKEEPRKVRF DYDLFLHLEG HPPVNHLRCE
     KLTFNNPTED FRRKLLKAGG DPNRSIHTSS SSSSSSSSSS SSSSSSSSSS SSSSSSSSSS
     SSSSSSSSSS TSFSKPHKLM KEHKEKPSKD SREHKSAFKE PSRDHNKSSK ESSKKPKENK
     PLKEEKIVPK MAFKEPKPMS KEPKPDSNLL TITSGQDKKA PSKRPPISDS EELSAKKRKK
     SSSEALFKSF SSAPPLILTC SADKKQIKDK SHVKMGKVKI ESETSEKKKS TLPPFDDIVD
     PNDSDVEENI SSKSDSEQPS PASSSSSSSS SFTPSQTRQQ GPLRSIMKDL HSDDNEEESD
     EVEDNDNDSE MERPVNRGGS RSRRVSLSDG SDSESSSASS PLHHEPPPPL LKTNNNQILE
     VKSPIKQSKS DKQIKNGECD KAYLDELVEL HRRLMTLRER HILQQIVNLI EETGHFHITN
     TTFDFDLCSL DKTTVRKLQS YLETSGTS
//
